新的体内研究数据！

Twist Bioscience 最近开展了临床前研究，旨在了解我们的抗体先导物在人体内对抗 COVID-19 所起的保护作用。数据显示了在临床前仓鼠给药模型中 ，施以 1 mg/kg 最低剂量的两种单域 VHH“纳米抗体”TB202-3 和 TB202-63，均防止了体重减轻。此外，TB181-36，Twist Bioscience 与 Vanderbilt 大学医学中心 (VUMC) 合作开发的一种 IgG 抗体，被发现可以防止体重减轻 5 mg/kg 和 10 mg/kg。

查看数据

Twist Biopharma COVID 抗体计划

Twist Biopharma has developed a set of antibodies that targets the SARS-CoV-2 Spike
Protein with high binding affinity and specificity.  Several antibodies also show the ability to
block S1 binding to ACE2.

We have also developed a set of antibodies targeting the extracellular domain of the ACE2
receptor. These antibodies have high binding affinity and have been demonstrated to inhibit
the binding of the S1 protein to ACE2 in vitro.  

All antibodies are fully human and are either hIgG1, IgG2, or IgG1 VHH Fc making them ideal
as potential candidates for both diagnostic and therapeutic uses.

其他信息

Please contact the Twist Biopharma team here for information regarding additional antibody information, requesting larger or custom quantities of antibodies or licensing questions. 

These products are subject to certain use restrictions set forth in Twist’s Supply Terms and Conditions and Antibody Supplemental Terms and Conditions.